Abivax: Nine Scientific Presentations on Obebazimod at DDW
Abivax announces nine scientific abstracts concerning obebazimod at the Digestive Disease Week, scheduled from May 2 to May 5, 2026, in Chicago. These data are derived from phase 3 of the ABTECT program and encompass efficacy, tolerance, and patient feedback on ulcerative colitis.
Comprehensive Coverage of Obebazimod's Impact
The scientific abstracts presented at the conference cover various areas: the efficacy and tolerance of obebazimod in patients with moderately to severely active ulcerative colitis, early symptom improvement, and outcomes observed in specific patient subgroups. Among the nine presentations are also data related to patient quality of life, including improvements in fatigue and overall quality of life reported at 8 weeks. Two abstracts focus on mechanisms of action: one presents preclinical data showing dual antifibrotic and anti-inflammatory activity, while the other reports changes in microRNA-124 expression and a reduction in inflammatory cytokines in patients.
Keynote and Poster Sessions
An oral presentation is scheduled for Monday, May 4, from 10:00 AM to 10:15 AM, focusing on the effect of obebazimod on histological and histological-endoscopic outcomes. Eight poster presentations will take place on Monday, May 4, and Tuesday, May 5, 2026, spread across various thematic sessions: controlled clinical trials, quality of life and psychosocial outcomes, as well as mechanisms of action of therapeutics in chronic inflammatory bowel diseases. The presentations will later be available on the publications page of the Abivax website.
